Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones.

Using 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one and 4,5-dihydroxy-1H-isoindole-1,3(2H)-dione based HIV-1 integrase inhibitors as display platforms, we undertook a thorough examination of the effects of modifying the halogen substituents on a key benzyl ring that is hypothesized to bind in a hydrophobic pocket of the integrase.DNA complex. Data from this study suggest that in general dihalo-substituted analogues have higher potency than monohalo-substituted compounds, but that further addition of halogens is not beneficial.

[1]  James M. Chen,et al.  Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[2]  M. Markowitz,et al.  Raltegravir: an integrase inhibitor for HIV-1 , 2008, Expert opinion on investigational drugs.

[3]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[4]  M. Rowley,et al.  Development of 2-t butyl-N-methyl pyrimidones as potent inhibitors of HIV integrase. , 2008, Bioorganic & Medicinal Chemistry Letters.

[5]  K. Hertogs,et al.  Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. , 2005, Journal of medicinal chemistry.

[6]  Y. Pommier,et al.  2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. , 2008, Journal of medicinal chemistry.

[7]  Yves Pommier,et al.  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. , 2008, Biochemistry.

[8]  Z. Debyser,et al.  Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. , 2009, Journal of medicinal chemistry.

[9]  N. Meanwell,et al.  Benzyl amide-ketoacid inhibitors of HIV-integrase. , 2007, Bioorganic & Medicinal Chemistry Letters.

[10]  B. Johns,et al.  Advances in two-metal chelation inhibitors of HIV integrase , 2008 .

[11]  D. Hazuda,et al.  8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[12]  U. Koch,et al.  From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. , 2007, Bioorganic & medicinal chemistry letters.

[13]  S. Swaminathan,et al.  Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. , 2008, Journal of molecular biology.

[14]  Satoru Ikeda,et al.  Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. , 2006, Journal of medicinal chemistry.

[15]  D. Hazuda,et al.  Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[16]  Michael Rowley,et al.  Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. , 2007, Journal of medicinal chemistry.